Sofgen Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Revenue	373.8	423.75	403.2	403.74	331.47
Revenue Growth (YoY)	-11.79%	5.10%	-0.13%	21.80%	2.05%
Cost of Revenue	182.32	185.77	168.08	174.14	140.15
Gross Profit	191.48	237.98	235.13	229.6	191.31
Selling, General & Admin	223.05	193.35	197.69	163.67	128.26
Other Operating Expenses	-3.1	-16.61	3.32	74.99	-
Operating Expenses	219.96	176.74	201.01	238.67	128.26
Operating Income	-28.48	61.24	34.11	-9.07	63.05
Interest Expense	-42.48	-40.85	-25.85	-85.58	-52.63
Interest & Investment Income	0.2	0.66	0.1	0.06	-
Currency Exchange Gain (Loss)	-17.83	24.37	-18.28	-5.99	-3.91
Other Non Operating Income (Expenses)	-0.97	2.88	1.88	2.18	-5.67
EBT Excluding Unusual Items	-89.55	48.3	-8.04	-98.41	0.85
Impairment of Goodwill	-	-5.79	-0.84	-	-
Gain (Loss) on Sale of Investments	12.65	11.19	61.8	4.51	-
Asset Writedown	-7.68	-7.73	-5.18	-	-
Pretax Income	-84.59	45.96	47.74	-93.9	0.85
Income Tax Expense	-16.29	5.62	11.61	13.09	11.3
Earnings From Continuing Operations	-68.3	40.34	36.13	-106.99	-10.45
Net Income	-68.3	40.34	36.13	-106.99	-10.45
Net Income to Common	-68.3	40.34	36.13	-106.99	-10.45
Net Income Growth	-	11.67%	-	-	-
Shares Outstanding (Basic)	100	101	101	98	97
Shares Outstanding (Diluted)	100	101	101	98	97
Shares Change (YoY)	-0.73%	-0.10%	3.02%	1.04%	-
EPS (Basic)	-0.68	0.40	0.36	-1.09	-0.11
EPS (Diluted)	-0.68	0.40	0.36	-1.09	-0.11
EPS Growth	-	11.79%	-	-	-
Free Cash Flow	69.05	87.3	-7.61	20.02	63.22
Free Cash Flow Per Share	0.69	0.86	-0.07	0.20	0.65
Gross Margin	51.23%	56.16%	58.31%	56.87%	57.72%
Operating Margin	-7.62%	14.45%	8.46%	-2.25%	19.02%
Profit Margin	-18.27%	9.52%	8.96%	-26.50%	-3.15%
Free Cash Flow Margin	18.47%	20.60%	-1.89%	4.96%	19.07%
EBITDA	-19.13	69.74	44.7	1.82	74.93
EBITDA Margin	-5.12%	16.46%	11.09%	0.45%	22.61%
D&A For EBITDA	9.35	8.5	10.59	10.89	11.88
EBIT	-28.48	61.24	34.11	-9.07	63.05
EBIT Margin	-7.62%	14.45%	8.46%	-2.25%	19.02%
Effective Tax Rate	-	12.22%	24.33%	-	1330.51%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.